At Juvena Therapeutics, we're not anti-aging.
Why? Because this untapped, underserved market represents an opportunity for major breakthroughs in scientific research, investment ventures, and the quality of how we live.
FAST FACTS ON THE
In 2010, the 65 and older population in the US was 40.2 million. By 2050, that number is expected to more than double to 88.5 million [...]
The United States spends more than $26 billion annually on additional health care costs for people over 65 who lose their ability to live independently over the course of a single year [...]
In 2000, 1.5 million people were institutionalized, and 33% of these people were admitted to long‐term health care facilities because of their inability to perform activities of daily living [...]
Increases in prevalence and treatment intensity of chronic disease are responsible for about 2/3 of the increase in health care costs over the past 20 years [...]
An older adults suffers a fall that requires an emergency room visit every 15 seconds. Every 29 minutes, an older American dies as a result of a fall [...]
BIOLOGICS ARE THE BEST
Aging is a treatable illness awaiting therapeutic solutions to reverse or prevent the cellular and organ-level accumulation of damage. At Juvena, we believe that biologics are the absolute best therapeutic approach. And the market is also tracking huge trends in support of the movement:
*Source: Genetic Engineering and Biotechnology News:
“The Top 25 Best-Selling Drugs of 2014”
The vibrant future of the aging market is in our hands.
To learn more about making a positive impact with us, email: